PMID- 26046396
OWN - NLM
STAT- MEDLINE
DCOM- 20160503
LR  - 20211203
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 7
IP  - 6
DP  - 2015 Jun 3
TI  - Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional 
      Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and 
      Atherosclerosis.
PG  - 4453-64
LID - 10.3390/nu7064453 [doi]
AB  - Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the 
      low-density lipoprotein receptor family and has a unique structure, which 
      facilitates its multiple functions as a co-receptor for Wnt/beta-catenin signaling 
      and as a ligand receptor for endocytosis. The role LRP6 plays in metabolic 
      regulation, specifically in the nutrient-sensing pathway, has recently garnered 
      considerable interest. Patients carrying an LRP6 mutation exhibit elevated levels 
      of LDL cholesterol, triglycerides, and fasting glucose, which cooperatively 
      constitute the risk factors of metabolic syndrome and atherosclerosis. Since the 
      discovery of this mutation, the general role of LRP6 in lipid homeostasis, 
      glucose metabolism, and atherosclerosis has been thoroughly researched. These 
      studies have demonstrated that LRP6 plays a role in LDL receptor-mediated LDL 
      uptake. In addition, when the LRP6 mutant impaired Wnt-LRP6 signaling, 
      hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis developed. 
      LRP6 regulates lipid homeostasis and body fat mass via the nutrient-sensing 
      mechanistic target of the rapamycin (mTOR) pathway. Furthermore, the mutant LRP6 
      triggers atherosclerosis by activating platelet-derived growth factor 
      (PDGF)-dependent vascular smooth muscle cell differentiation. This review 
      highlights the exceptional opportunities to study the pathophysiologic 
      contributions of LRP6 to metabolic syndrome and cardiovascular diseases, which 
      implicate LRP6 as a latent regulator of lipid metabolism and a novel therapeutic 
      target for nutritional intervention.
FAU - Go, Gwang-woong
AU  - Go GW
AD  - Department of Food and Nutrition, Kookmin University, Seoul 136-702, Korea. 
      gwgo@kookmin.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150603
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Cholesterol, LDL)
RN  - 0 (LRP6 protein, human)
RN  - 0 (Low Density Lipoprotein Receptor-Related Protein-6)
RN  - 0 (Receptors, LDL)
RN  - 0 (Triglycerides)
RN  - 0 (beta Catenin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/diet therapy/*genetics
MH  - Cholesterol, LDL/blood
MH  - Disease Models, Animal
MH  - Gene Targeting/*methods
MH  - Homeostasis
MH  - Humans
MH  - Hyperlipidemias/diet therapy/*genetics
MH  - Lipid Metabolism/genetics
MH  - Low Density Lipoprotein Receptor-Related Protein-6/genetics/*metabolism
MH  - Non-alcoholic Fatty Liver Disease/diet therapy/*genetics
MH  - Receptors, LDL/genetics/metabolism
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
MH  - Triglycerides/blood
MH  - Wnt Signaling Pathway
MH  - beta Catenin/genetics/metabolism
PMC - PMC4488795
OTO - NOTNLM
OT  - LRP6
OT  - atherosclerosis
OT  - dyslipidemia
OT  - non-alcoholic fatty liver disease
EDAT- 2015/06/06 06:00
MHDA- 2016/05/04 06:00
PMCR- 2015/06/01
CRDT- 2015/06/06 06:00
PHST- 2015/03/05 00:00 [received]
PHST- 2015/05/13 00:00 [revised]
PHST- 2015/05/27 00:00 [accepted]
PHST- 2015/06/06 06:00 [entrez]
PHST- 2015/06/06 06:00 [pubmed]
PHST- 2016/05/04 06:00 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - nu7064453 [pii]
AID - nutrients-07-04453 [pii]
AID - 10.3390/nu7064453 [doi]
PST - epublish
SO  - Nutrients. 2015 Jun 3;7(6):4453-64. doi: 10.3390/nu7064453.